Advancing novel antibody-drug conjugates
Progressing portfolios of therapeutics from discovery through development and onto the market requires extensive clinical, regulatory and manufacturing expertise. Few biotechnology companies possess this infrastructure and rely on outsourced partners or major pharmaceutical companies to advance development programs.
Reflecting the significant potential of our cancer antibody-drug conjugates (ADCs) we have established a major innovative collaboration, which provides a strategic alternative to these traditional development routes. This unique approach is complemented by a number of partnerships with global pharmaceutical companies, which validate our proprietary cancer targeting and antibody discovery technologies.